News & Press

Freespira raises $10M to eliminate panic attacks & PTSD symptoms.

Palo Alto Health Sciences, Inc. has a new name, Freespira, Inc.
Visit the site

Freespira, Inc. raised $10 million in new funding led by Lightspeed Venture Partners to further commercialize Freespira, the 28-day digital therapeutic treatment for panic attacks and PTSD.
View Press Release

The white paper, It’s Not “All in Your Head” A physiological approach to treating panic attacks and PTSD, was published.
Download White Paper

VIVA 2019: Perivascular temsirolimus could be “viable alternative” to prevent restenosis in BTK lesions

Joint Purification Systems Sucessfully Completes Enrollment in its Phase 2 Multicenter Feasibility Trial

Palo Alto Health Science’s Freespira Drives Significant Medical, Emergency Room and Medication Costs in Large Health Plan Quality Improvement Program

Congratulations to Dean Harmon, Brooks Pate, et al for their publication in Nature showcasing Harmon’s selective deuteration process, measured by MRR

Providence Medical Technology Announces First Patient Enrollment in the “FUSE” IDE Clinical Study

The FUSE Study is designed to demonstrate the superiority of Circumferential Cervical Fusion over traditional ACDF in patients at high risk for nonunion or revisions.

Providence Medical Technology , Jun 15, 2020, 06:00 ET

PLEASANTON, Calif.June 15, 2020 /PRNewswire/ — Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes of the cervical spine, announced initiation of enrollment in a human clinical Investigational Device Exemption (IDE) study evaluating the safety and effectiveness of its Posterior Cervical Stabilization System (PCSS) in patients with 3-level degenerative disc disease. The first case was performed by Dr. Pierce Nunley, MD, Director of the Spine Institute of Louisiana in Shreveport, Louisiana.

Continue Reading

Providence Medical Technology Secures $25 Million In Equity Financing

Proceeds to Bolster Commercial Expansion & Clinical Development of its DTRAX® Spinal System

Providence Medical Technology, Inc.   Sep 20, 2018, 06:00 ET
PLEASANTON, Calif.Sept. 20, 2018 /PRNewswire/ — Providence Medical Technology, Inc., an innovator in tissue-sparing surgical equipment and implants for cervical spine fusion surgery, today announced the closing of $25 million in new equity financing. Revelation Partners led the round with participation from the private equity investment team at BMO Global Asset Management (EMEA), MVM Life Science Partners, Medvest Capital, and Aphelion Capital. Inclusive of this new investment, Providence has raised a total of $53 million in equity financing since its 2008 inception.

Continue Reading

Joint Purification Systems, Inc. Announces $7.8 Million Series A Financing

Joint Purification Systems Inc. announced today that it has closed a $7.8 million Series A financing.


Joint Purification Systems Inc. (JPS), an early stage medical device company developing novel combination products to treat chronic peri-prosthetic joint infection (PJI), announced today that it has closed a $7.8 million Series A financing. The financing was led by Johnson & Johnson Innovation – JJDC, Inc. MedVest Fund II was also a new investor in the round. Proceeds will be used for preparation of the company’s first products in the X7 Spacer System for initiation of human clinical studies.

Continue Reading

Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris Pharmaceuticals Co.

Capital will fuel continued research and clinical development of micro-infusion platform

EMERYVILLE, Calif.June 21, 2018 /PRNewswire/ — Mercator MedSystems, Inc., today announced it has received $11 million in Series D equity financing led by Shenzhen Salubris Pharmaceuticals Co. (Salubris), with participation from current Mercator investors and other undisclosed new investors. The new funding will further advance the clinical development of Mercator’s proprietary micro-infusion catheter systems and accelerate the company’s vision of improving outcomes in patients around the world with cardiovascular and pulmonary disease.

Continue Reading

Mercator Medsystems leaps forward with Bullfrog into LIMBO-ATX trial

BioWorld MedTech, November 1, 2017

View Article

Scroll to top